Denali Therapeutics began a phase Ia clinical trial for SAR443060 (DNL747), a small-molecule, selective, orally bioavailable, central nervous system (CNS)-penetrant, reversible RIPK1 inhibitor, phase Ib/IIa trials in amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) followed [143]. Here, RIPK1 is linked to amyotrophic lateral sclerosis.